Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAb114 Safety and PK in Healthy Adults
NCT03478891Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2018
- Primary completion
- Mar 2019
- Countries
- 1
01
Overview
Phase 1, open-label trial of ansuvimab in Ebola virus disease (EVD) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Subjects Experiencing Infusion Reaction During Product Administration at 30 minutes, Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms Within 3 Days and 3 more. Started May 2018; status: completed.
02
Drugs
ansuvimab
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT03478891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03478891.